neflamapimod
neflamapimod: developed by 1 company · 4 clinical trials tracked.
neflamapimod evidence translation
What we can confirm
4 tracked trials
What it means
What to watch
Prepared research question
How could neflamapimod → CRVO affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| CervoMed Inc. (CRVO) dementia with Lewy bodies (DLB) | Phase 2 |
Clinical Trials (4)
A Phase 2a Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients With Primary Progressive Aphasia (PPA)
Primary endpoint: Incidence of Adverse Events and Serious Adverse Events.
A Double-Blind, Placebo-Controlled, Proof-of-Concept Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod on Recovery After Moderate to Severe Acute Ischaemic Stroke
Primary endpoint: Change from baseline to Week 12 in Fugl-Meyer Assessment of Motor Recovery after Stroke (FMMS) motor score (upper and lower) and total score
An Open-Label Phase 2a Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients With Dementia With Lewy Bodies (DLB)
Primary endpoint: Evaluate the safety and tolerability 80 mg neflamapimod given twice daily in patients with dementia with Lewy bodies.
A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients With Dementia With Lewy Bodies
Primary endpoint: Change in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) in neflamapimod-treated subjects compared to placebo recipients.
Frequently asked questions
Who is developing neflamapimod?
neflamapimod is being developed by CervoMed Inc..
How many clinical trials involve neflamapimod?
BioSniper tracks 4 clinical trials involving neflamapimod.